MMMariana de Oliveira Marques

Mariana de Oliveira Marques

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariana de Oliveira Marques has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • André Abdo

    Department of Hematology Hospital Alemão Oswaldo Cruz São Paulo SP Brazil

    2 shared publications
  • Gisele W. Braga Colleoni

    Department of Clinical and Experimental Oncology Federal University of São Paulo São Paulo SP Brazil

    2 shared publications
  • Karin Zattar Cecyn

    Department of Clinical and Experimental Oncology Federal University of São Paulo São Paulo SP Brazil

    2 shared publications
  • Amilton Silva Junior

    Hosp Alema Oswaldo Cruz, Brasil Sao Paulo, Joao Julio 331, Sao Paulo, Brazil

    1 shared publication
  • Arnaldo Lopes Colombo

    Department of Medicine, Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo , São Paulo

    1 shared publication
  • Caina D. de Liz

    Department of Hematology Hospital Sírio Libanês São Paulo SP Brazil

    1 shared publication

Latest Publications

  • Open Access

    Immune reconstitution inflammatory syndrome‐associated lymphoma: A retrospective Brazilian cohort

    by Juliano Cordova Vargas, Karin Zattar Cecyn, Mariana de Oliveira Marques, Juliana Pereira, Walter M. Tobias Braga, Nelson Hamerschlak, Jacques Tabacof, Caina D. de Liz, André Abdo, Paulo Roberto Abrão Ferreira, et al.

    After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence, clinical features and prognosis of IRIS-associated lymphomas in Brazilian patients. Incidence in 2000-2019 was 9.8% (27/276 patients with HIV and lymphoma; viral load drop >1 log). Time between HIV diagnosis and cART initiation was <1 year in 70.3% of cases. Time between cART initiation and lymphoma diagnosis was <3 months in 11 cases and 3-6 months in 16 cases. Overall and progression-free survival rates were similar between cases of non-IRIS-associated lymphoma and IRIS-associated lymphoma.


  • Soluble CD137 as a potential biomarker for severe COVID-19

    by Mariana de Oliveira Marques, André Abdo, Priscilla Brito Silva, Amilton Silva Junior, Lucas Bassolli de Oliveira Alves, José Victor Gomes Costa, Josiane Martin, Philip Bachour, Otavio C.G. Baiocchi


  • Open Access

    Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach

    by Maria Daniela Bergamasco, Carlos Alberto P. Pereira, Celso Arrais-Rodrigues, Diogo B. Ferreira, Otavio Baiocchi, Fabio Kerbauy, Marcio Nucci, Arnaldo Lopes Colombo

    Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with mold-active azoles has been challenged recently because of drug–drug interactions with novel targeted therapies. This is a retrospective, single-center cohort study of consecutive cases of proven or probable IFD, diagnosed between 2009 and 2019, in adult hematologic patients and HCT recipients managed with fluconazole prophylaxis and an antifungal diagnostic-driven approach for mold infection. During the study period, 94 cases of IFD occurred among 664 hematologic patients and 316 HCT recipients. The frequency among patients with allogeneic HCT, autologous HCT, acute leukemia and other hematologic malignancies was 8.9%, 1.6%, 17.3%, and 6.4%, respectively. Aspergillosis was the leading IFD (53.2%), followed by fusariosis (18.1%), candidiasis (10.6%), and cryptococcosis (8.5%). The overall 6-week mortality rate was 37.2%, and varied according to the host and the etiology of IFD, from 28% in aspergillosis to 52.9% in fusariosis. Although IFD occurred frequently in our cohort of patients managed with an antifungal diagnostic driven approach, mortality rates were comparable to other studies. In the face of challenges posed by the use of anti-mold prophylaxis, this strategy remains a reasonable alternative.


  • Long-term outcomes of ocular adnexal lymphomas: case series from two lymphoma centers in Brazil

    by Mariana de Oliveira Marques, Paulo Goes Manso, Raphael L. C. Araujo, Fábio Do Nascimento Brito, Jamille Elita de Castro Cunha Herculani, Giovanna Garzon Dias Lemos, Milena Almendra Rodrigues, Luiz Fernando Teixeira, Kleber Simões Do Espirito Santo, Yara de Menezes, et al.

    Ocular adnexal lymphoma (OAL) refers to extremely rare, heterogeneous, malignant lymphoproliferative disorder that accounts for 55% of all orbital tumors and 5% of extranodal lymphomas. OAL can com...